DexCom, Inc. Price & Performance (DXCM)

Dexcom's recent FDA warning letter highlighted quality issues at its U.S. manufacturing sites, raising concerns about compliance. Despite these setbacks, the company remains optimistic about its financial outlook and continues to expand its market presence. Corrective actions are underway, aiming to mitigate regulatory risks without disrupting production.123

Dexcom has seen an uptick in insider selling activity, raising questions among investors. Recent data shows a decrease in shareholder sentiment, with short interest rising by 4.11% this month. Analysts, however, maintain a "Moderate Buy" consensus, citing long-term growth potential in the CGM market.456

Dexcom’s G7 CGM system has achieved a notable 8.0% MARD, positioning it as the most accurate sensor in the market. This development strengthens its appeal among healthcare providers, who increasingly favor technology over traditional medication for diabetes management, according to a recent ATTD 2025 report.789